Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bioventix ( (GB:BVXP) ) has provided an announcement.
Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock, has purchased 61 ordinary shares of the company under a dividend reinvestment plan. The purchase slightly increased Hiscock’s stake in the company to approximately 0.02 percent of the issued share capital, demonstrating a continued commitment to the company’s growth and market position.
More about Bioventix
Bioventix plc is a UK-based company that specializes in the development and commercial supply of high-affinity monoclonal antibodies, primarily for applications in clinical diagnostics.
YTD Price Performance: -22.66%
Average Trading Volume: 8,136
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £167M
For an in-depth examination of BVXP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue